LYRA实时信号 | 通过Getagraph.com最大化利润

购买 107653 min ago

@ $4.78

发出时间: 15 Feb 2024 @ 04:33

回报率: 3.14%

上一信号: Feb 10 - 03:49

上一信号: 出售

回报率: 2.36 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:43):

Stats
今日成交量	40 274.00
平均成交量	347 629
市值	294.53M
EPS	$0 ( 2024-04-03 )
下一个收益日期	( $-0.260 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.91
ATR14	$0.0200 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Waksal Harlan	Buy	275 000	Common Stock
2024-03-18	Palasis Maria	Buy	500 000	Stock Option
2024-01-30	Bishop John E	Buy	200 000	Stock Options
2024-01-30	Nieman Richard	Buy	200 000	Stock Options
2024-01-30	Cavalier Jason	Buy	200 000	Stock Options

INSIDER POWER
100.00
Last 92 transactions
Buy: 35 062 945 \| Sell: 0

音量相关性

長: -0.03 (neutral)

短: 0.21 (neutral)

Signal:(58.901) Neutral

Lyra Therapeutics Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Lyra Therapeutics Inc 相关性 - 货币/商品

0.28
( neutral )

-0.55
( weak negative )

0.00
( neutral )

-0.31
( neutral )

-0.27
( neutral )

0.48
( neutral )

Lyra Therapeutics Inc 财务报表

Annual	2023
营收:	$1.56M
毛利润:	$1.28M (82.16 %)
EPS:	$-1.260

FY	2023
营收:	$1.56M
毛利润:	$1.28M (82.16 %)
EPS:	$-1.260

FY	2022
营收:	$1.36M
毛利润:	$296 000 (21.72 %)
EPS:	$-1.830

FY	2021
营收:	$285 000
毛利润:	$0.00 (0.00 %)
EPS:	$-3.35

Financial Reports:

No articles found.

Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.